TREATMENT OF KAWASAKI DISEASE--PULSE IV METHYLPREDNISOLONE VS IVIG

川崎病的治疗--PULSE IV甲泼尼龙VS IVIG

• 批准号: 6120816
• 负责人: ROBERT SUNDEL
• 金额: $ 3.04万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6120816
• 关键词: cardiovascular disorder diagnosis; child (0-11); clinical research; clinical trial phase I; hormone therapy; human subject; human therapy evaluation; hyperthermia; immunoglobulins; immunotherapy; intravenous administration; methylprednisolone; mucocutaneous lymph node syndrome; skin disorder diagnosis

Children diagnosed with Kawasaki disease prior to the eighth day of fever will be randomized to receive traditional therapy, intravenous immunoglobulin (IVIG) 2 g/kg over 8-12 hours, or experimental therapy, intravenous methyprednisolone (IVMP), 30 mg/kg in D5W over 2 hours on each of two consecutive days. All children will otherwise receive treatment according to current standards of care. Any child receiving either IVIG or IVMP therapy who is febrile 48 hours after treatment will receive IVIG (salvage therapy), according to current treatment guidelines.

诊断为川崎病的儿童在出生的第八天之前